Host inflammatory response to SARS-CoV-2

宿主对 SARS-CoV-2 的炎症反应

基本信息

  • 批准号:
    10192439
  • 负责人:
  • 金额:
    $ 26.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Each year, humans encounter a variety of seasonal corona viruses that cause minor symptoms similar to the common cold. In contrast, SARS-CoV-2, which is responsible for COVID-19 (coronavirus disease 2019), has caused more than 110,000 deaths in the United States alone as of June 4, 2020. For unknown reasons, COVID- 19 disease severity is extremely variable, with many infected individuals experiencing mild symptoms including sore throat, headache, and cough or no symptoms at all. However, a significant number of infected individuals experience severe disease, including acute respiratory distress syndrome, renal failure, cardiac arrest, and gastrointestinal distress. Importantly, SARS-CoV-2 infection can trigger a hyperactive immune response that results in a cytokine storm, which is a massive release of pro-inflammatory molecules that can cause fatal tissue damage and likely causes the most severe disease symptoms. What triggers and regulates a cytokine storm is unclear, and studies are needed to reveal the processes by which SARS-CoV-2 induces inflammation, and how SARS-CoV-2 infection imparts COVID19 disease. Thus, the overarching goal of this proposal is to determine how inflammatory responses to SARS-CoV-2 are generated. To address this goal, we propose the following Specific Aims: 1. Define the inflammatory cytokine response induced by SARS-CoV-2. We will evaluate cytokine production from cells infected with SARS-CoV-2 using cell lines derived from lung and immune cells that populate the lung. Additionally, because severe COVID-19 patients present with elevated levels of the cytokine IL-1β and because IL-1β is released following the inflammatory form of cell death known as pyroptosis, we will assess the ability of SARS-CoV-2 to stimulate pyroptosis. We will then use CRISPR-based gene knockout and pharmacologic inhibitors to map the molecular pathways required for production and release of the observed cytokines. 2. Determine the inflammatory transcriptome across infected and bystander cells in propagating and amplifying inflammatory responses to CoV2. Using single cell RNA sequencing, we will assay mixed populations of cells with infected and non-infected (bystander) cells to determine how virus infection imparts inflammatory gene expression and how inflammatory signals from infected cells affect neighboring uninfected cells to amplify the inflammatory response. Sequencing and bioinformatics analyses will be conducted by the Gale lab transcriptomics and computational biology team, and results will be validated by complimentary techniques. From these studies, we expect to reveal the inflammatory cytokine signaling events following SARS-CoV-2 infection. These studies will also provide biomarkers to identify patients susceptible to cytokine storm and will identify gene or gene network/pathway targets to inform strategies to treat COVID-19 disease.
每年,人类都会遇到各种季节性冠状病毒,这些病毒会引起类似于 普通感冒相比之下,导致COVID-19(2019年冠状病毒病)的SARS-CoV-2, 截至2020年6月4日,仅在美国就造成超过11万人死亡。由于未知的原因,COVID- 19疾病的严重程度变化很大,许多感染者出现轻微症状,包括 喉咙痛,头痛,咳嗽或没有任何症状。然而,相当数量的感染者 患有严重疾病,包括急性呼吸窘迫综合征、肾衰竭、心脏骤停,以及 胃肠道不适重要的是,SARS-CoV-2感染可引发过度活跃的免疫反应, 导致细胞因子风暴,这是一种大量释放的促炎分子,可导致致命的组织 损害,并可能导致最严重的疾病症状。触发和调节细胞因子风暴的是 尚不清楚,需要研究来揭示SARS-CoV-2诱导炎症的过程,以及如何 SARS-CoV-2感染导致COVID 19疾病。因此,本提案的总体目标是确定 如何产生对SARS-CoV-2的炎症反应。为了实现这一目标,我们提出以下建议: 具体目标: 1.定义SARS-CoV-2诱导的炎症细胞因子反应。我们将评估细胞因子 使用来自肺和免疫细胞的细胞系从感染SARS-CoV-2的细胞中生产, 肺此外,由于严重的COVID-19患者存在细胞因子IL-1β水平升高, 由于IL-1β是在细胞死亡的炎症形式(称为细胞焦亡)后释放的,我们将评估IL-1β在细胞凋亡中的作用。 SARS-CoV-2刺激细胞凋亡的能力。然后,我们将使用基于CRISPR的基因敲除, 药理学抑制剂,以绘制所观察到的药物的产生和释放所需的分子途径。 细胞因子 2.确定增殖和增殖过程中感染细胞和旁观者细胞的炎性转录组, 增强对CoV 2的炎症反应。使用单细胞RNA测序,我们将检测混合 感染和未感染(旁观者)细胞的细胞群,以确定病毒感染如何赋予 炎症基因表达以及来自感染细胞的炎症信号如何影响邻近未感染细胞 细胞来放大炎症反应。测序和生物信息学分析将由 Gale实验室转录组学和计算生物学团队,结果将由免费验证 技术. 通过这些研究,我们期望揭示SARS-CoV-2后的炎症细胞因子信号传导事件 感染这些研究还将提供生物标志物,以识别易受细胞因子风暴影响的患者, 确定基因或基因网络/通路靶标,为治疗COVID-19疾病提供信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Gale其他文献

Michael Gale的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Gale', 18)}}的其他基金

Core C: Systems Biology Core
核心 C:系统生物学核心
  • 批准号:
    10723638
  • 财政年份:
    2023
  • 资助金额:
    $ 26.48万
  • 项目类别:
Project 2: Systems biology analyses of RHCMV/SIV and IL-15 mechanisms of immune programming
项目2:RHCMV/SIV和IL-15免疫编程机制的系统生物学分析
  • 批准号:
    10723640
  • 财政年份:
    2023
  • 资助金额:
    $ 26.48万
  • 项目类别:
MECHANISMS PROGRAMMING PROTECTIVE IMMUNITY FROM RhCMV-SIV VACCINE AND IL-15 ACTIONS
RhCMV-SIV 疫苗和 IL-15 作用的保护性免疫编程机制
  • 批准号:
    10723635
  • 财政年份:
    2023
  • 资助金额:
    $ 26.48万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10723636
  • 财政年份:
    2023
  • 资助金额:
    $ 26.48万
  • 项目类别:
Omics, Bioinformatics, and Data Management Core
组学、生物信息学和数据管理核心
  • 批准号:
    10709011
  • 财政年份:
    2022
  • 资助金额:
    $ 26.48万
  • 项目类别:
Omics, Bioinformatics, and Data Management Core
组学、生物信息学和数据管理核心
  • 批准号:
    10619301
  • 财政年份:
    2022
  • 资助金额:
    $ 26.48万
  • 项目类别:
University of Washington Arboviral Research Network (UWARN)
华盛顿大学虫媒病毒研究网络 (UWARN)
  • 批准号:
    10687434
  • 财政年份:
    2022
  • 资助金额:
    $ 26.48万
  • 项目类别:
University of Washington Arboviral Research Network (UWARN)
华盛顿大学虫媒病毒研究网络 (UWARN)
  • 批准号:
    10493552
  • 财政年份:
    2021
  • 资助金额:
    $ 26.48万
  • 项目类别:
University of Washington Arboviral Research Network (UWARN)
华盛顿大学虫媒病毒研究网络 (UWARN)
  • 批准号:
    10770598
  • 财政年份:
    2020
  • 资助金额:
    $ 26.48万
  • 项目类别:
University of Washington Arboviral Research Network (UWARN)
华盛顿大学虫媒病毒研究网络 (UWARN)
  • 批准号:
    10170249
  • 财政年份:
    2020
  • 资助金额:
    $ 26.48万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 26.48万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了